qfx Newsflash: on July 14, BitMine dropped the bombshell that they scored all this crypto goodness right after closing a $250 million private placement. Apparently, they decided that chasing electric rates was so last season, and opted for Ethereum like it was the latest trend on a Paris runway.
Fedwire, the U.S. central bank’s real-time gross settlement system, is joining the 21st century by adopting this standard to enhance cross-border payments 🌎. It’s about time, don’t you think? I mean, who doesn’t love faster, more secure, and interoperable payments? 💸
Yet, with a wave of his hand, a Coinbase executive has categorically denied such claims. A veritable drama unfolding, reminiscent of ancient conflicts where honor was stained with whispers and backroom dealings.
As investors anticipate a potential “altcoin season” several tokens like NEAR are reaping the rewards. NEAR jumped from $2.55 to $2.66 in the past 24 hours, representing a 7% range.
Meanwhile, bitcoin is taking a leisurely stroll with just a slight uptick to an annualized implied volatility of 46%. Anticipating a more gentle bump of around 6%, it seems our favorite cryptocurrency is on vacation while XRP is racing the Indy 500! 🏎️
Source – Farside Investors
One of the most intriguing developments behind this surge is the increased activity from so-called “accumulator” addresses. According to top analyst Darkfost, these wallets, known for their relentless accumulation of BTC without a single sell order, have hit a new record high in 2025. These addresses are often associated with high-conviction holders, including long-term retail investors, institutional participants, and funds with a strategic vision. 🕵️♂️
These memecoins, forever wading in the murky waters of excitement and purpose, now face their reckoning. Take Floki [FLOKI], with its grand aspirations of FlokiFi; it’s like a puppy trying to bark its way into the world of serious finance. Is it bringing in the bacon, or just barking up the wrong tree? 🐶💔
According to Coinbase’s chief legal officer, Paul Grewal, the exchange played no part in the Bloomberg piece. He stated on X that Coinbase “absolutely did not contribute to this story.”
In a recent press release, it was announced that Sonnet BioTherapeutics, a Nasdaq-listed biotech firm, has agreed to an $888 million business combination with Rorschach I LLC, a newly formed entity backed by Atlas Merchant Capital and Paradigm. This bold move will see Sonnet pivot into a crypto treasury strategy, leaving behind its traditional biotech roots.
